Myasthenia Gravis Comprehensive Study Notes

Overview of Myasthenia Gravis (MG)

  • Definition and Origin
        * Myasthenia Gravis is a chronic autoimmune neuromuscular disease.
        * Etymology: The name is derived from Latin and Greek meaning ‐grave muscle weakness.‐
        * Core characteristic: Muscle weakness that increases with physical activity and improves after periods of rest.
        * Primary site of dysfunction: A disorder at the neuron junction that interferes with the transmission of Acetylcholine (ACHACH).

Anatomic Alterations and Pathophysiology

  • Mechanical Interference
        * MG involves the neuromuscular junction, specifically interfering with the transmission of ACHACH between the axonal terminal and the receptor sites of voluntary muscles.
        * The body produces its own antibodies (specifically IgGIgG antibodies) that block the ACHACH receptor sites.
  • Mechanism of Chemical Transmission Disruption
        * The antibodies block ACHACH from reaching the receptor sites of the muscular cell.
        * The antibodies accelerate the breakdown of ACHACH.
        * The antibodies destroy the receptor sites entirely.
  • Secondary Anatomic Alterations of the Lungs
        * If ventilatory failure is not properly managed, the following can occur:
            * Mucous accumulation
            * Airway obstruction
            * Alveolar consolidation
            * Atelectasis (a common secondary anatomic alteration)
  • Targeted Muscle Groups
        * The disease mainly affects voluntary muscles, including:
            * Eyelids and eyes.
            * Facial movement (chewing and talking).
            * Muscles controlling breathing.
            * Neck and limb muscles.
        * In severe cases, diaphragmatic paralysis and ventilatory failure may develop.

Etiology and Demographics

  • Prevalence
        * In the United States, there are approximately 2020 people with Myasthenia Gravis for every 100,000100,000 people.
  • Demographics
        * Most common in young women: Usually under the age of 4040 (specifically between ages 1515 to 3535).
        * Most common in older men: Usually over the age of 6060 (specifically between ages 4040 to 7070).
  • Provoking Factors for Clinical Manifestations
        * Emotional upset
        * Physical stress
        * Exposure to extreme temperature changes
        * Febrile illness
        * Pregnancy

Diagnosis and Testing

  • Diagnostic Modalities
        * Clinical history of weakness in specific areas and decreased strength throughout the day.
        * Neurologic examination.
        * Electromyography (EMGEMG).
        * Blood analysis (searching for ACHACH receptor antibodies).
        * Computed Tomography (CTCT) or Magnetic Resonance Imaging (MRIMRI).
  • Ice Pack Test
        * Used specifically for patients with ptosis (droopy eye).
        * Involves the application of an ice pack for 55 minutes to observe improvement in eyelid drooping.
  • Edrophonium (Tensilon) Challenge
        * Used to diagnose MG and monitor drug therapy levels.
        * Case 1: Improvement (Myasthenic Crisis)
            * If symptoms improve with Tensilon, it is referred to as a Myasthenic Crisis.
            * Indicates a need for more anticholinesterase drug therapy.
            * Maintenance drugs: Neostigmine (Prostigmin) and Pyridostigmine (Mestinon, Regonol).
        * Case 2: Worsened Symptoms (Cholinergic Crisis)
            * If symptoms worsen with Tensilon, it is referred to as a Cholinergic Crisis.
            * Indicates that too much medication has been administered.
            * Treatment: Administer Atropine to reverse the effects of Tensilon and relieve symptoms of the cholinergic crisis.

Clinical History and Physical Examination

  • Hallmark Symptoms
        * Chronic muscle fatigue.
        * Facial muscle weakness.
        * Ptosis: Drooping of one or both eyelids.
        * Diplopia: Double vision.
        * Dysphagia: Difficulty swallowing.
        * Difficulty speaking, chewing, and breathing.
        * Unstable gait.
        * Weakness in arms, hands, fingers, legs, and neck, especially after repetitive motions.
  • Respiratory Impact
        * Muscles of the diaphragm and chest wall can weaken, impairing ventilation.
        * Impairment of deep breathing and coughing predisposes the patient to excessive bronchial secretions, pneumonia, and atelectasis.
  • Physical Exam Findings
        * General weakness: Often described as ‐mind to ground.‐
        * Respiratory rate: Varies based on the degree of muscle paralysis; may lead to apnea in severe cases.
        * Cyanosis.
        * Decreasing VTV_T, VCVC, and MIPMIP.
        * Chest assessment: Diminished breath sounds, crackles, and rhonchi.

Cardiopulmonary and Laboratory Findings

  • Pulmonary Function Test (PFT)
        * Pattern: Moderate to Severe Restrictive Lung Pathophysiology.
        * Measured values (all decreased):
            * Tidal Volume (VTV_T): Decreased
            * Inspiratory Reserve Volume (IRVIRV): Decreased
            * Expiratory Reserve Volume (ERVERV): Decreased
            * Residual Volume (RVRV): Decreased
            * Vital Capacity (VCVC): Decreased
            * Inspiratory Capacity (ICIC): Decreased
            * Functional Residual Capacity (FRCFRC): Decreased
            * Total Lung Capacity (TLCTLC): Decreased
        * RV/TLCRV/TLC ratio: Normal.
        * Negative Inspiratory Pressure (NIPNIP) / Force: Decreased.
  • Arterial Blood Gases (ABG)
        * Indicates Acute Ventilatory Failure with Hypoxemia (Acute Respiratory Acidosis) in moderate to severe cases.
        * pHpH: Decreased.
        * PaCO2PaCO_2: Increased.
        * HCO3HCO_3: Slightly increased.
        * PaO2PaO_2: Decreased.
  • Radiologic Findings
        * Early stage: Typically normal.
        * Advanced stage: Increased opacity when atelectasis is present.

General Management and Therapeutic Protocols

  • Monitoring
        * Frequent measurements required: VCVC, NIFNIF, Blood Pressure, Pulse Oximetry (SpO2SpO_2), and ABGABG.
  • Respiratory Care Protocols
        * Oxygen Therapy: Increase FiO2FiO_2 up to 60%60\%. If higher support is needed, add CPAP/PEEPCPAP/PEEP.
        * Hyperinflation Therapy: Example: IPPBIPPB (Intermittent Positive Pressure Breathing) used for atelectasis.
        * Airway Management: Bronchopulmonary Hygiene and Lung Expansion Therapy protocols to prevent mucus accumulation.
        * Mechanical Ventilation: Initiated when clinical data demonstrate impending or acute ventilatory failure.
  • Indicators for Acute Ventilatory Failure
        * Vital Capacity (VCVC) < 20 mL/kg20\,mL/kg.     * Negative Inspiratory Force (NIFNIF) < −30 cm H2O-30\,cm\,H_2O.     * pHpH < 7.357.35 or PaCO2PaCO_2 > 45 mm Hg45\,mm\,Hg.
  • Medical and Surgical Treatments
        * Historical note: First attempt to treat MG recorded on June 2nd, 1935.
        * Cholinesterase inhibitors.
        * Immunosuppressants.
        * Adrenocorticotropic hormone therapy.
        * Thymectomy: Removal of the thymus gland (questioned whether this is a cure or just stops progression).
        * Plasmapheresis.

Questions and Discussion

  • Anatomic Site of Problem: The fundamental anatomic alteration in MG is a problem with voluntary muscle acetylcholine (ACHACH) transmission.
  • Pathologic Mechanism: IgGIgG (not IgEIgE) antibodies cause weakness by blocking ACHACH sites, destroying sites, or accelerating ACHACH breakdown; they do not break down the nerves' myelin sheath.
  • Major Lung Changes: The major pathologic changes associated with ventilatory failure in MG are alveolar consolidation and atelectasis.
  • Chest Assessment Findings: Common findings include diminished breath sounds, crackles, and rhonchi.
  • Most Important Assessment for Ventilatory Failure: Negative Inspiratory Force (NIFNIF) is critical for determining acute ventilatory failure peaks.